Bevacizumab in combination with taxane versus non-taxane containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer a systematic review

Madhusmita Behera, Rathi N. Pillai, Taofeek K. Owonikoko, Sungjin Kim, Conor Steuer, Zhengjia Chen, Nabil F. Saba, Chandra Belani, Fadlo R. Khuri, Suresh S. Ramalingam

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Background: In preclinical studies, the efficacy of the combination of antiangiogenic agents with chemotherapy seems to be dependent on the specific cytotoxic agent. We conducted a systematic review of the efficacy of bevacizumab in combination with taxane or nontaxane containing regimens for untreated, nonsquamous non-smallcell lung cancer patients. Methods: An extensive search of published clinical trials was conducted from electronic databases (MEDLINE, EMBASE, and Cochrane) and meeting proceedings using relevant search criteria. Phase 2 and randomized trials reporting on the efficacy of bevacizumab combined with taxane or non-taxane regimens were selected. A systematic analysis of extracted data was performed using Comprehensive Meta-Analysis (Version 2.2) software. Clinical outcome in patients treated with taxane versus non-taxane regimen was compared using point estimates for weighted values of median overall survival, progression-free survival, and response rate. Results: Twenty-nine studies reported between 2005 and 2015 were eligible. A total of 5890 patients (2767 and 3123 in the taxane and non-taxane groups, respectively) were included. The taxane and non-taxane groups were comparable in patient characteristics: median age, 62.8 versus 61.2 years; males, 57% versus 58%; adenocarcinomas, 83% versus 83%; stage IV, 87% versus 82%; performance status 0/1- 45/55% versus 41/59%, respectively. The weighted median overall survival was 14.4 versus 13.7 months (p = 0.5); progression-free survival was 6.93 versus 6.99 months (p = 0.61); response rate was 41% versus 39% (p = 0.65) for taxane and non-taxane groups. Conclusions: The outcomes between taxane and non-taxane regimens when given in combination with bevacizumab for patients with nonsquamous non-small-cell lung cancer are comparable.

Original languageEnglish (US)
Pages (from-to)1142-1147
Number of pages6
JournalJournal of Thoracic Oncology
Volume10
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Disease-Free Survival
Angiogenesis Inhibitors
Survival
Cytotoxins
Bevacizumab
taxane
MEDLINE
Meta-Analysis
Lung Neoplasms
Adenocarcinoma
Software
Survival Rate
Clinical Trials
Databases
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Behera, Madhusmita ; Pillai, Rathi N. ; Owonikoko, Taofeek K. ; Kim, Sungjin ; Steuer, Conor ; Chen, Zhengjia ; Saba, Nabil F. ; Belani, Chandra ; Khuri, Fadlo R. ; Ramalingam, Suresh S. / Bevacizumab in combination with taxane versus non-taxane containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer a systematic review. In: Journal of Thoracic Oncology. 2015 ; Vol. 10, No. 8. pp. 1142-1147.
@article{700d7000d71d46e3bf5ef5ecd76dd8d1,
title = "Bevacizumab in combination with taxane versus non-taxane containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer a systematic review",
abstract = "Background: In preclinical studies, the efficacy of the combination of antiangiogenic agents with chemotherapy seems to be dependent on the specific cytotoxic agent. We conducted a systematic review of the efficacy of bevacizumab in combination with taxane or nontaxane containing regimens for untreated, nonsquamous non-smallcell lung cancer patients. Methods: An extensive search of published clinical trials was conducted from electronic databases (MEDLINE, EMBASE, and Cochrane) and meeting proceedings using relevant search criteria. Phase 2 and randomized trials reporting on the efficacy of bevacizumab combined with taxane or non-taxane regimens were selected. A systematic analysis of extracted data was performed using Comprehensive Meta-Analysis (Version 2.2) software. Clinical outcome in patients treated with taxane versus non-taxane regimen was compared using point estimates for weighted values of median overall survival, progression-free survival, and response rate. Results: Twenty-nine studies reported between 2005 and 2015 were eligible. A total of 5890 patients (2767 and 3123 in the taxane and non-taxane groups, respectively) were included. The taxane and non-taxane groups were comparable in patient characteristics: median age, 62.8 versus 61.2 years; males, 57{\%} versus 58{\%}; adenocarcinomas, 83{\%} versus 83{\%}; stage IV, 87{\%} versus 82{\%}; performance status 0/1- 45/55{\%} versus 41/59{\%}, respectively. The weighted median overall survival was 14.4 versus 13.7 months (p = 0.5); progression-free survival was 6.93 versus 6.99 months (p = 0.61); response rate was 41{\%} versus 39{\%} (p = 0.65) for taxane and non-taxane groups. Conclusions: The outcomes between taxane and non-taxane regimens when given in combination with bevacizumab for patients with nonsquamous non-small-cell lung cancer are comparable.",
author = "Madhusmita Behera and Pillai, {Rathi N.} and Owonikoko, {Taofeek K.} and Sungjin Kim and Conor Steuer and Zhengjia Chen and Saba, {Nabil F.} and Chandra Belani and Khuri, {Fadlo R.} and Ramalingam, {Suresh S.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1097/JTO.0000000000000572",
language = "English (US)",
volume = "10",
pages = "1142--1147",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "8",

}

Bevacizumab in combination with taxane versus non-taxane containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer a systematic review. / Behera, Madhusmita; Pillai, Rathi N.; Owonikoko, Taofeek K.; Kim, Sungjin; Steuer, Conor; Chen, Zhengjia; Saba, Nabil F.; Belani, Chandra; Khuri, Fadlo R.; Ramalingam, Suresh S.

In: Journal of Thoracic Oncology, Vol. 10, No. 8, 01.08.2015, p. 1142-1147.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bevacizumab in combination with taxane versus non-taxane containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer a systematic review

AU - Behera, Madhusmita

AU - Pillai, Rathi N.

AU - Owonikoko, Taofeek K.

AU - Kim, Sungjin

AU - Steuer, Conor

AU - Chen, Zhengjia

AU - Saba, Nabil F.

AU - Belani, Chandra

AU - Khuri, Fadlo R.

AU - Ramalingam, Suresh S.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background: In preclinical studies, the efficacy of the combination of antiangiogenic agents with chemotherapy seems to be dependent on the specific cytotoxic agent. We conducted a systematic review of the efficacy of bevacizumab in combination with taxane or nontaxane containing regimens for untreated, nonsquamous non-smallcell lung cancer patients. Methods: An extensive search of published clinical trials was conducted from electronic databases (MEDLINE, EMBASE, and Cochrane) and meeting proceedings using relevant search criteria. Phase 2 and randomized trials reporting on the efficacy of bevacizumab combined with taxane or non-taxane regimens were selected. A systematic analysis of extracted data was performed using Comprehensive Meta-Analysis (Version 2.2) software. Clinical outcome in patients treated with taxane versus non-taxane regimen was compared using point estimates for weighted values of median overall survival, progression-free survival, and response rate. Results: Twenty-nine studies reported between 2005 and 2015 were eligible. A total of 5890 patients (2767 and 3123 in the taxane and non-taxane groups, respectively) were included. The taxane and non-taxane groups were comparable in patient characteristics: median age, 62.8 versus 61.2 years; males, 57% versus 58%; adenocarcinomas, 83% versus 83%; stage IV, 87% versus 82%; performance status 0/1- 45/55% versus 41/59%, respectively. The weighted median overall survival was 14.4 versus 13.7 months (p = 0.5); progression-free survival was 6.93 versus 6.99 months (p = 0.61); response rate was 41% versus 39% (p = 0.65) for taxane and non-taxane groups. Conclusions: The outcomes between taxane and non-taxane regimens when given in combination with bevacizumab for patients with nonsquamous non-small-cell lung cancer are comparable.

AB - Background: In preclinical studies, the efficacy of the combination of antiangiogenic agents with chemotherapy seems to be dependent on the specific cytotoxic agent. We conducted a systematic review of the efficacy of bevacizumab in combination with taxane or nontaxane containing regimens for untreated, nonsquamous non-smallcell lung cancer patients. Methods: An extensive search of published clinical trials was conducted from electronic databases (MEDLINE, EMBASE, and Cochrane) and meeting proceedings using relevant search criteria. Phase 2 and randomized trials reporting on the efficacy of bevacizumab combined with taxane or non-taxane regimens were selected. A systematic analysis of extracted data was performed using Comprehensive Meta-Analysis (Version 2.2) software. Clinical outcome in patients treated with taxane versus non-taxane regimen was compared using point estimates for weighted values of median overall survival, progression-free survival, and response rate. Results: Twenty-nine studies reported between 2005 and 2015 were eligible. A total of 5890 patients (2767 and 3123 in the taxane and non-taxane groups, respectively) were included. The taxane and non-taxane groups were comparable in patient characteristics: median age, 62.8 versus 61.2 years; males, 57% versus 58%; adenocarcinomas, 83% versus 83%; stage IV, 87% versus 82%; performance status 0/1- 45/55% versus 41/59%, respectively. The weighted median overall survival was 14.4 versus 13.7 months (p = 0.5); progression-free survival was 6.93 versus 6.99 months (p = 0.61); response rate was 41% versus 39% (p = 0.65) for taxane and non-taxane groups. Conclusions: The outcomes between taxane and non-taxane regimens when given in combination with bevacizumab for patients with nonsquamous non-small-cell lung cancer are comparable.

UR - http://www.scopus.com/inward/record.url?scp=84942868816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942868816&partnerID=8YFLogxK

U2 - 10.1097/JTO.0000000000000572

DO - 10.1097/JTO.0000000000000572

M3 - Review article

VL - 10

SP - 1142

EP - 1147

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 8

ER -